Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
about
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's diseaseAltered transcription factor trafficking in oxidatively-stressed neuronal cells.Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice.Norepinephrine loss produces more profound motor deficits than MPTP treatment in miceSensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.Murine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication.Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.Strengths and limitations of genetic mouse models of Parkinson's disease.Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing miceAdenylyl cylases 1 and 8 mediate select striatal-dependent behaviors and sensitivity to ethanol stimulation in the adolescent period following acute neonatal ethanol exposure.Behavioral phenotyping of mouse models of Parkinson's disease.5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.Treadmill gait analysis does not detect motor deficits in animal models of Parkinson's disease or amyotrophic lateral sclerosis.Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrationResveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidationCognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?25-Hydroxyvitamin D depletion does not exacerbate MPTP-induced dopamine neuron damage in mice.Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated miceBehavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.The 5-HT(2A) Receptor Antagonist M100907 Produces Antiparkinsonian Effects and Decreases Striatal Glutamate.Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system.MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis.Animal models of the non-motor features of Parkinson's disease.Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's diseaseSelective damage to dopaminergic transporters following exposure to the brominated flame retardant, HBCDDPerinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum.Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol.Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.Dopamine-dependent compensation maintains motor behavior in mice with developmental ablation of dopaminergic neurons.Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's disease.WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse.TracMouse: A computer aided movement analysis script for the mouse inverted horizontal grid testSynaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide.
P2860
Q24629942-0310EB23-61EC-4F7C-B707-FE4B7563E64AQ30419484-6E762A5A-ADBA-4650-A8B8-4DDEC9B2207FQ30470435-D2E72B7C-8892-4DE6-848A-2863CC53C3B1Q30478183-1D8CCD3A-059D-49BF-85E9-B97E231F340CQ30479999-DE1B6F16-9B86-425C-B59B-FF7D1A56808FQ30512976-195ED806-533C-4ABB-9001-7A8EAA9BDD88Q30519556-6A48F5C9-8518-44FE-81B3-14C3117B5301Q33312931-6F2DA892-6474-4BA7-AFEE-4C6812130CB4Q33347250-91D02554-410F-4DE2-B164-1CBD574A3A5BQ33680232-E3B708A0-75D7-4446-A800-6360611E95F9Q33819097-9DF4EB05-6FBD-4FFD-808E-6620BAF8C111Q33820609-2D7B25D3-3912-4E9C-A401-4CD7ED528A5AQ33886545-AB29B50F-2325-4BFE-AD38-97542BEE7373Q33911605-F11ADBCD-C9B1-4827-A2CE-2454414EC6E1Q34037199-57758B22-7F05-4C44-AE87-0C1D2AD4C8C7Q34119079-1692D5EC-8999-4BA9-A32B-C3EC75AE815BQ34307633-21A3D270-341A-4A5B-AD30-B999C65CAC94Q34328940-A8948F0A-F8EE-4F5E-8A7F-9D3496170D6FQ34476803-2E12A60B-FE8E-4178-9A1E-036B89A0657EQ34595165-F2EC0059-770C-4EE0-BEE9-15B00915108DQ34762041-F1CD0588-411E-47CA-A198-7C33D4B75C6CQ35025876-6FF66641-40B8-4A13-9D39-4F1D7239C8FCQ35051346-991FCFC0-7958-4EE3-B39B-8D3270EF3ED0Q35850734-9E415132-77F5-413D-8F65-226B2233332FQ36157573-C528914E-800D-41DF-99B9-245A64BA0202Q36235578-E3970E1E-6BCD-4242-A63E-55A1BA6EE6E3Q36276997-F991E7CB-C8A2-4056-9FF9-24DBBCB694A4Q36366275-72A35C0F-EC55-4B3A-B4DD-34ADB182BB06Q36584927-D34E988B-3F3B-496A-8A14-9B3FAA71CABCQ36704078-07A2EE45-BAC1-4E61-A7BA-20F788766EEAQ36787223-5DE3CC5B-BE9F-45F3-AB01-36FFCC633650Q36994063-37DDB984-E20A-426D-8E87-16FAEB21823EQ37251953-265864F1-5260-48FE-BA27-96994DA93D41Q37298364-548D4237-2899-4354-9159-41BD24D96A55Q37371387-0509A0C7-8428-41F4-99B4-D7537B4D9F29Q37441397-E854A6A4-91C1-4A2A-97D5-E577EACF645FQ37502418-8CCA2D59-7867-41C6-8C20-FC75270B806FQ37508349-43E8A340-6C66-4786-A580-FF61A60036D9Q37711589-C5E5D2EB-D4CA-40B0-941E-D04D65373E0CQ38617000-90D6E6D5-1DA3-4535-937D-4A0EF464479E
P2860
Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Detection of behavioral impair ...... yl-1,2,3,6-tetrahydropyridine.
@en
Detection of behavioral impair ...... yl-1,2,3,6-tetrahydropyridine.
@nl
type
label
Detection of behavioral impair ...... yl-1,2,3,6-tetrahydropyridine.
@en
Detection of behavioral impair ...... yl-1,2,3,6-tetrahydropyridine.
@nl
prefLabel
Detection of behavioral impair ...... yl-1,2,3,6-tetrahydropyridine.
@en
Detection of behavioral impair ...... yl-1,2,3,6-tetrahydropyridine.
@nl
P2093
P356
P1476
Detection of behavioral impair ...... yl-1,2,3,6-tetrahydropyridine.
@en
P2093
Gary W Miller
Jennifer L Tillerson
Maria E Reverón
W Michael Caudle
P356
10.1006/EXNR.2002.8021
P407
P577
2002-11-01T00:00:00Z